251
|
Genetic Predisposition to Neuroblastoma. CHILDREN-BASEL 2018; 5:children5090119. [PMID: 30200332 PMCID: PMC6162470 DOI: 10.3390/children5090119] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 08/22/2018] [Accepted: 08/28/2018] [Indexed: 02/07/2023]
Abstract
Neuroblastoma is the most common solid tumor in children under the age of one. It displays remarkable phenotypic heterogeneity, resulting in differences in outcomes that correlate with clinical and biologic features at diagnosis. While neuroblastoma accounts for approximately 5% of all cancer diagnoses in pediatrics, it disproportionately results in about 9% of all childhood deaths. Research advances over the decades have led to an improved understanding of neuroblastoma biology. However, the initiating events that lead to the development of neuroblastoma remain to be fully elucidated. It has only been recently that advances in genetics and genomics have allowed researchers to unravel the predisposing factors enabling the development of neuroblastoma and fully appreciate the interplay between the genetics of tumor and host. In this review, we outline the current understanding of familial neuroblastoma and highlight germline variations that predispose children to sporadic disease. We also discuss promising future directions in neuroblastoma genomic research and potential clinical applications for these advances.
Collapse
|
252
|
Frank S, Nelson P, Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Res 2018; 7. [PMID: 30135717 PMCID: PMC6073096 DOI: 10.12688/f1000research.14499.1] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/24/2018] [Indexed: 12/13/2022] Open
Abstract
Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes (
ERG,
PTEN, and
SPOP) are recurrently mutated in more than 10% of primary tumors. On the other hand, metastatic castration-resistant tumors have more mutations, but, with the exception of the androgen receptor gene (
AR), no single gene is altered in more than half of tumors. Structural genomic rearrangements are common, including
ERG fusions, copy gains involving the
MYC locus, and copy losses containing
PTEN. Overall, instead of being associated with a single dominant driver event, prostate tumors display various combinations of modifications in oncogenes and tumor suppressors. This review takes a broad look at the recent advances in PCa research, including understanding the genetic alterations that drive the disease and how specific mutations can sensitize tumors to potential therapies. We begin with an overview of the genomic landscape of primary and metastatic PCa, enabled by recent large-scale sequencing efforts. Advances in three-dimensional cell culture techniques and mouse models for PCa are also discussed, and particular emphasis is placed on the benefits of patient-derived xenograft models. We also review research into understanding how ETS fusions (in particular,
TMPRSS2-ERG) and
SPOP mutations contribute to tumor initiation. Next, we examine the recent findings on the prevalence of germline DNA repair mutations in about 12% of patients with metastatic disease and their potential benefit from the use of poly(ADP-ribose) polymerase (PARP) inhibitors and immune modulation. Lastly, we discuss the recent increased prevalence of AR-negative tumors (neuroendocrine and double-negative) and the current state of immunotherapy in PCa. AR remains the primary clinical target for PCa therapies; however, it does not act alone, and better understanding of supporting mutations may help guide the development of novel therapeutic strategies.
Collapse
Affiliation(s)
- Sander Frank
- Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Peter Nelson
- Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.,Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.,Departments of Medicine and Urology, University of Washington, Seattle, WA 98195, USA.,Department of Pathology, University of Washington, Seattle, WA 98195, USA
| | - Valeri Vasioukhin
- Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.,Department of Pathology, University of Washington, Seattle, WA 98195, USA
| |
Collapse
|
253
|
Mazon M, Larouche V, St-Louis M, Schindler D, Carreau M. Elevated blood levels of Dickkopf-1 are associated with acute infections. IMMUNITY INFLAMMATION AND DISEASE 2018; 6:428-434. [PMID: 30028084 PMCID: PMC6247238 DOI: 10.1002/iid3.232] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Accepted: 07/03/2018] [Indexed: 01/15/2023]
Abstract
INTRODUCTION Dickkopf-1 (DKK1) is a soluble protein and antagonist of the Wnt/β-catenin signaling pathway. DKK1 is found elevated in serum from patients affected with various types of cancers and in some instances, it is considered a diagnostic and prognostic biomarker. Elevated serum levels of DKK1 have also been detected in animal models of chronic inflammatory diseases. Previous work from our laboratory has demonstrated upregulation of DKK1 in cells and mouse models of the bone marrow failure (BMF) and cancer-prone disease Fanconi anemia (FA). The present study aimed to investigate whether DKK1 blood levels in patients are associated with FA or inflammatory responses to acute infections. METHODS Plasma samples were collected from 58 children admitted to the Centre Mère-Enfant Soleil du Centre Hospitalier de Québec-Université Laval with signs of acute infections. Blood plasma specimens were also collected from healthy blood donors at the Héma-Québec blood donor clinic. Plasmas from patients diagnosed with FA were also included in the study. DKK1 levels in blood plasmas were assessed by standard ELISA. RESULTS Patients with acute infections showed dramatically high levels of DKK1 (6072 ± 518 pg/ml) in their blood compared to healthy blood donors (1726 ± 95 pg/ml). No correlations were found between DKK1 levels and C reactive protein (CRP) concentration, platelet numbers, or white blood cell counts. Patients with FA showed higher DKK1 plasma levels (3419 ± 147.5 pg/ml) than healthy blood donors (1726 ± 95 pg/ml) but significantly lower than patients with acute infections. CONCLUSION These findings suggest that blood DKK1 is elevated in response to infections and perhaps to inflammatory responses.
Collapse
Affiliation(s)
- Melody Mazon
- Centre Hospitalier de Québec-Université Laval Research Center, Québec, G1V 4G2, Canada
| | - Valérie Larouche
- Centre Hospitalier de Québec-Université Laval Research Center, Québec, G1V 4G2, Canada.,Department of Pediatrics, Université Laval, Québec, G1V 0A6, Canada
| | | | - Detlev Schindler
- Department of Human Genetics, University of Wurzburg, Wurzburg 97070, Germany
| | - Madeleine Carreau
- Centre Hospitalier de Québec-Université Laval Research Center, Québec, G1V 4G2, Canada.,Department of Pediatrics, Université Laval, Québec, G1V 0A6, Canada
| |
Collapse
|
254
|
Kasraian Z, Trompezinski S, Cario-André M, Morice-Picard F, Ged C, Jullie ML, Taieb A, Rezvani HR. Pigmentation abnormalities in nucleotide excision repair disorders: Evidence and hypotheses. Pigment Cell Melanoma Res 2018; 32:25-40. [PMID: 29938913 DOI: 10.1111/pcmr.12720] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 05/11/2018] [Accepted: 06/11/2018] [Indexed: 12/12/2022]
Abstract
Skin pigmentation abnormalities are manifested in several disorders associated with deficient DNA repair mechanisms such as nucleotide excision repair (NER) and double-strand break (DSB) diseases, a topic that has not received much attention up to now. Hereditary disorders associated with defective DNA repair are valuable models for understanding mechanisms that lead to hypo- and hyperpigmentation. Owing to the UV-associated nature of abnormal pigmentary manifestations, the outcome of the activated DNA damage response (DDR) network could be the effector signal for alterations in pigmentation, ultimately manifesting as pigmentary abnormalities in repair-deficient disorders. In this review, the role of the DDR network in the manifestation of pigmentary abnormalities in NER and DSB disorders is discussed with a special emphasis on NER disorders.
Collapse
Affiliation(s)
- Zeinab Kasraian
- NAOS, Aix en Provence, France.,Univ. Bordeaux, Inserm, BMGIC, UMR 1035, Bordeaux, France
| | | | - Muriel Cario-André
- Univ. Bordeaux, Inserm, BMGIC, UMR 1035, Bordeaux, France.,Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, Bordeaux, France
| | - Fanny Morice-Picard
- Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, Bordeaux, France.,Service de Dermatologie Adulte et Pédiatrique, CHU de Bordeaux, Bordeaux, France
| | - Cécile Ged
- Univ. Bordeaux, Inserm, BMGIC, UMR 1035, Bordeaux, France.,Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, Bordeaux, France
| | | | - Alain Taieb
- Univ. Bordeaux, Inserm, BMGIC, UMR 1035, Bordeaux, France.,Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, Bordeaux, France.,Service de Dermatologie Adulte et Pédiatrique, CHU de Bordeaux, Bordeaux, France
| | - Hamid Reza Rezvani
- Univ. Bordeaux, Inserm, BMGIC, UMR 1035, Bordeaux, France.,Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, Bordeaux, France
| |
Collapse
|
255
|
Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia. Blood Cancer J 2018; 8:50. [PMID: 29891941 PMCID: PMC6002376 DOI: 10.1038/s41408-018-0090-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 04/17/2018] [Accepted: 04/30/2018] [Indexed: 12/12/2022] Open
|
256
|
de Cárcer G, Huertas P, López-Contreras AJ. Chromosome instability: From molecular mechanisms to disease. DNA Repair (Amst) 2018. [DOI: 10.1016/j.dnarep.2018.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
257
|
Minguillón J, Surrallés J. Therapeutic research in the crystal chromosome disease Fanconi anemia. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2018; 836:104-108. [PMID: 30389152 DOI: 10.1016/j.mrgentox.2018.05.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 04/18/2018] [Accepted: 05/07/2018] [Indexed: 01/10/2023]
Abstract
In the last decades there has been a great progress in understanding the pathological and genetic mechanisms involved in Fanconi anemia (FA), a rare disease characterized by chromosome fragility, congenital malformations, bone marrow failure (BMF) and high cancer predisposition. However, these advances have not gone in parallel with the development of medical treatments, with the exception of improved protocols of hematopoietic stem cell transplant (HSCT). BMF and hematological malignancies are the most important and life threatening conditions the patient suffer during the first and second decade of life, respectively, being HSCT the only curative treatment available. Solid tumors are the third hallmark of the disease, usually with poor prognosis as tumor resection is the only therapeutic option given that patients do not tolerate chemotherapy or radiation. With improved HSCT protocols, FA patient survival has increased, leading to a progressively increased number of solid malignancies in adult patients. Therapeutic research is currently focused in targeted therapies for solid tumors as well as in preventive options in the context of drug repurposing. This review summarizes current therapies and drugs used so far in clinical trials to treat Fanconi anemia, as well as the ones used in FA research with potential for future therapeutic opportunities including drugs that suppress chromosome fragility or are expected to delay the onset of BMF and cancer in Fanconi anemia.
Collapse
Affiliation(s)
- Jordi Minguillón
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Genetics Department and Biomedical Research Institute Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, 08193 Bellaterra, Spain.
| | - Jordi Surrallés
- Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; Genetics Department and Biomedical Research Institute Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, 08193 Bellaterra, Spain.
| |
Collapse
|